Please assess the completion status of the following clinical trial:

Trial Title: BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males and females aged \>=18 and =\<80 years at Screening who have a diagnosis of moderate to severely active Crohn's Disease (CD), confirmed by endoscopy or radiologic evaluation, for more than 4 months with evidence of mucosal ulceration. Patients must have all of the following:~  * Crohn's Disease Activity Index (CDAI) score of \>=220 and =\<450~ * A diagnosis of Crohn's Disease (CD) confirmed by ileocolonoscopy during Screening~ * Presence of mucosal ulcers in at least one segment of the ileum or colon and a SES-CD score ≥7 (for patients with isolated ileal disease SES-CD score ≥4), as assessed by ileocolonoscopy and confirmed by central independent reviewer(s) before randomization~* Anti-tumor necrosis factor (TNF) patients or patients previously treated with infliximab who had initially responded and who meet one of the following criteria:~  * Responded and developed secondary resistance due confirmed anti-infliximab anti-drug antibody formation, which caused infliximab depletion~ * Responded and became intolerant~* Further inclusion criteria apply~Exclusion criteria:~* Patients with ulcerative colitis or indeterminate colitis~* Patients with symptomatic known obstructive strictures~* Surgical bowel resection performed within 6 months prior to Screening or planned resection at any time while enrolled in the trial~* Patients with an ostomy or ileoanal pouch~* Patients with short bowel syndrome~* Patients who have previously used infliximab and have never clinically responded~* Patients who have previously received treatment with adalimumab, or who have participated in an adalimumab or adalimumab biosimilar clinical trial~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 695501 (Type: EXPERIMENTAL): None
- HUMIRA + BI 695501 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).